This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ORPN Bioblast Pharma (ORPN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock About Bioblast Pharma Stock (NASDAQ:ORPN) 30 days 90 days 365 days Advanced Chart Remove Ads Get Bioblast Pharma alerts:Sign Up Key Stats Today's Range$0.87▼$0.9250-Day Range$11.50▼$28.4952-Week Range$6.16▼$30.00Volume22,291 shsAverage VolumeN/AMarket Capitalization$386,400.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEnlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.Read More… Remove Ads Receive ORPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioblast Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ORPN Stock News HeadlinesPositive Outlook on BridgeBio Pharma’s BBP-812 Gene Therapy: Buy Rating ReaffirmedOctober 25, 2024 | markets.businessinsider.comPromising Outlook and Strategic Growth Support Buy Rating for Catalyst PharmaOctober 19, 2024 | markets.businessinsider.comThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.April 11, 2025 | Colonial Metals (Ad)Positive Developments and Potential Upside for BridgeBio Pharma: An Overweight Rating on Acoramidis Approval Prospects and Pipeline CatalystsOctober 18, 2024 | markets.businessinsider.com'Biopharma Crescent' sees rapid expansion fueled by recent investmentsOctober 12, 2024 | msn.comBuy Rating Affirmed on Urogen Pharma’s Promising Pipeline and Market Expansion PotentialOctober 4, 2024 | markets.businessinsider.comPharmaceutical giant partners with biotech company to produce animal-free protein for global nutrition: 'A win-win combination'September 27, 2024 | msn.comA weight loss drug developer's stock soars after a $198 million IPOSeptember 26, 2024 | msn.comSee More Headlines ORPN Stock Analysis - Frequently Asked Questions When did Bioblast Pharma's stock split? Bioblast Pharma's stock reverse split on the morning of Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Bioblast Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioblast Pharma investors own include Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), SELLAS Life Sciences Group (SLS), Immunomedics (IMMU), Athersys (ATHX), ContraFect (CFRX) and Corbus Pharmaceuticals (CRBP). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ORPN CIK1596812 Webbioblastpharma.com Phone(722) 670-8072FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.56 per share Price / Book0.12Miscellaneous Outstanding Shares420,000Free FloatN/AMarket Cap$386,400.00 OptionableNot Optionable Beta1.41 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ORPN) was last updated on 4/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.